2,829 research outputs found
ONE -POT ALKOXYMERCURATION-BROMODEMERCURIATION: A VERSATILE ACCESS TO 3-ALKOXY-2-BROMOPROPANOIC ESTERS
Can the new and old drugs exert an immunomodulatory effect in acute myeloid leukemia?
Acute myeloid leukemia (AML) is considered an immune-suppressive neoplasm capable of evading immune surveillance through cellular and environmental players. Increasing knowledge of the immune system (IS) status at diagnosis seems to suggest ever more attention of the crosstalk between the leukemic clone and its immunologic counterpart. During the last years, the advent of novel immunotherapeutic strategies has revealed the importance of immune dysregulation and suppression for leukemia fitness. Considering all these premises, we reviewed the “off-target” effects on the IS of different drugs used in the treatment of AML, focusing on the main advantages of this interaction. The data reported support the idea that a successful therapeutic strategy should consider tailored approaches for performing leukemia eradication by both direct blasts killing and the engagement of the IS
Inside the biology of early T-cell precursor acute lymphoblastic leukemia: the perfect trick
Early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) is a rare, distinct subtype of T-ALL characterized by genomic instability, a dismal prognosis and refractoriness to standard chemotherapy. Since its first description in 2009, the expanding knowledge of its intricate biology has led to the definition of a stem cell leukemia with a combined lymphoid-myeloid potential: the perfect trick. Several studies in the last decade aimed to better characterize this new disease, but it was recognized as a distinct entity only in 2016. We review current insights into the biology of ETP-ALL and discuss the pathogenesis, genomic features and their impact on the clinical course in the precision medicine era today
FLT3 mutational analysis in acute myeloid leukemia: Advantages and pitfalls with different approaches
FMS-like tyrosine kinase 3 (FLT3) is one of the most closely studied genes in blood diseases. Numerous methods have been adopted for analyses, mainly in acute myeloid leukemia (AML) diagnostic work-up. According to international recommendations, the current gold standard approach allows FLT3 canonical mutations to be investigated, providing the main information for risk assessment and treatment choice. However, the technological improvements of the last decade have permitted “black side” gene exploration, revealing numerous hidden aspects of its role in leukemogenesis. The advent of the next-generation sequencing era emphasizes lights and shadows of FLT3 conventional mutational analysis, highlighting the need for a more comprehensive study of the gene. However, more extensive analysis is opening new, unexplored questions whose impact on clinical outcomes is still unknown. The present work is focused on the main topics regarding FLT3 mutational analysis in AML, debating the strengths and weaknesses of the current gold standard approach. The rights and wrongs of NGS introduction in clinical practice will be discussed, showing that a more extensive knowledge of FLT3 mutational status could lead to reconsidering its role in AML management
Epitranscriptomics in normal and malignant hematopoiesis
Epitranscriptomics analyze the biochemical modifications borne by RNA and their downstream influence. From this point of view, epitranscriptomics represent a new layer for the control of genetic information and can affect a variety of molecular processes including the cell cycle and the differentiation. In physiological conditions, hematopoiesis is a tightly regulated process that produces differentiated blood cells starting from hematopoietic stem cells. Alteration of this process can occur at different levels in the pathway that leads from the genetic information to the phenotypic manifestation producing malignant hematopoiesis. This review focuses on the role of epitranscriptomic events that are known to be implicated in normal and malignant hematopoiesis, opening a new pathophysiological and therapeutic scenario. Moreover, an evolutionary vision of this mechanism will be provided
Nanopore Sequencing in Blood Diseases: A Wide Range of Opportunities
The molecular pathogenesis of hematological diseases is often driven by genetic and epigenetic alterations. Next-generation sequencing has considerably increased our genomic knowledge of these disorders becoming ever more widespread in clinical practice. In 2012 Oxford Nanopore Technologies (ONT) released the MinION, the first long-read nanopore-based sequencer, overcoming the main limits of short-reads sequences generation. In the last years, several nanopore sequencing approaches have been performed in various “-omic” sciences; this review focuses on the challenge to introduce ONT devices in the hematological field, showing advantages, disadvantages and future perspectives of this technology in the precision medicine era
Genomic segmental duplications on the basis of the t(9;22) rearrangement in chronic myeloid leukemia
n/
Multi-GeV Electron Spectrometer
The advance in laser plasma acceleration techniques pushes the regime of the
resulting accelerated particles to higher energies and intensities. In
particular the upcoming experiments with the FLAME laser at LNF will enter the
GeV regime with almost 1pC of electrons. From the current status of
understanding of the acceleration mechanism, relatively large angular and
energy spreads are expected. There is therefore the need to develop a device
capable to measure the energy of electrons over three orders of magnitude (few
MeV to few GeV) under still unknown angular divergences. Within the PlasmonX
experiment at LNF a spectrometer is being constructed to perform these
measurements. It is made of an electro-magnet and a screen made of
scintillating fibers for the measurement of the trajectories of the particles.
The large range of operation, the huge number of particles and the need to
focus the divergence present unprecedented challenges in the design and
construction of such a device. We will present the design considerations for
this spectrometer and the first results from a prototype.Comment: 7 pages, 6 figures, submitted to NIM
ADAMTS2 gene dysregulation in T/myeloid mixed phenotype acute leukemia.
Background: Mixed phenotype acute leukemias (MPAL) include acute leukemias with blasts that express antigens
of more than one lineage, with no clear evidence of myeloid or lymphoid lineage differentiation. T/myeloid (T/My)
MPAL not otherwise specified (NOS) is a rare leukemia that expresses both T and myeloid antigens, accounting
for less than 1% of all leukemias but 89% of T/My MPAL. From a molecular point of view, very limited data are
available on T/My MPAL NOS.
Case presentation: In this report we describe a T/My MPAL NOS case with a complex rearrangement involving
chromosomes 5 and 14, resulting in overexpression of the ADAM metallopeptidase with thrombospondin type 1
motif, 2 (ADAMTS2) gene due to its juxtaposition to the T cell receptor delta (TRD) gene segment.
Conclusion: Detailed molecular cytogenetic characterization of the complex rearrangement in the reported T/My
MPAL case allowed us to observe ADAMTS2 gene overexpression, identifying a molecular marker that may be useful
for monitoring minimal residual disease. To our knowledge, this is the first evidence of gene dysregulation due to a
chromosomal rearrangement in T/My MPAL NOS.
Keywords: Mixed phenotype acute leukemia, ADAMTS2, TRD, Complex chromosomal rearrangement, Promoter
swapping, Gene dysregulatio
Absolute quantification of the pretreatment PML-RARA transcript defines the relapse risk in acute promyelocytic leukemia.
In this study we performed absolute quantification of the PML-RARA transcript by droplet digital polymerase chain reaction (ddPCR) in 76 newly diagnosed acute promyelocytic leukemia (APL) cases to verify the prognostic impact of the PML-RARA initial molecular burden. ddPCR analysis revealed that the amount of PML-RARA transcript at diagnosis in the group of patients who relapsed was higher than in that with continuous complete remission (CCR) (272 vs 89.2 PML-RARA copies/ng, p = 0.0004, respectively). Receiver operating characteristic analysis detected the optimal PML-RARA concentration threshold as 209.6 PML-RARA/ng (AUC 0.78; p < 0.0001) for discriminating between outcomes (CCR versus relapse). Among the 67 APL cases who achieved complete remission after the induction treatment, those with > 209.6 PML-RARA/ng had a worse relapse-free survival (p = 0.0006). At 5-year follow-up, patients with > 209.6 PML-RARA/ng had a cumulative incidence of relapse of 50.3% whereas 7.5% of the patients with suffered a relapse (p < 0.0001). Multivariate analysis identified the amount of PML-RARA before induction treatment as the sole independent prognostic factor for APL relapse.
Our results show that the pretreatment PML-RARA molecular burden could therefore be used to improve risk stratification in order to develop more individualized treatment regimens for high-risk APL cases
- …